Edesa Biotech (EDSA) 10-Q 10 Aug 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Jun. 30, 2015	Aug. 01, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Stellar Biotechnologies, Inc.
Entity Central Index Key	1,540,159
Entity Filer Category	Accelerated Filer
Trading Symbol	SBOTF
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Document Period End Date	Jun. 30, 2015
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015
Document Type	10-Q
Entity Common Stock, Shares Outstanding		79,546,650

Condensed Interim Consolidated

Condensed Interim Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Current assets:
Cash and cash equivalents	$ 10,161,458	$ 13,769,953	$ 13,427,404
Accounts receivable	$ 112,964	44,159	56,575
Short-term investments		448,632	$ 458,098
Inventory	$ 194,367	34,891
Prepaid expenses	256,402	125,840	$ 128,593
Total current assets	10,725,191	14,423,475	14,070,670
Noncurrent assets:
Property, plant and equipment, net	471,927	388,340	387,392
Deposits	15,900	15,900	15,900
Total noncurrent assets	487,827	404,240	403,292
Total Assets	11,213,018	14,827,715	14,473,962
Current liabilities:
Accounts payable and accrued liabilities	371,200	585,047	526,626
Deferred revenue	173,333	86,667	15,000
Warrant liability, current portion	1,235,905	460	879,040
Total current liabilities	$ 1,780,438	672,174	1,420,666
Long-term liabilities:
Warrant liability, less current portion		3,690,806	5,352,663
Total Liabilities	$ 1,780,438	$ 4,362,980	$ 6,773,329
Commitments (Note 7)
Shareholders' equity:
Common shares, unlimited common shares authorized, no par value, 79,546,650, 79,419,850 and 78,268,850 issued and outstanding at June 30, 2015, September 30, 2014 and August 31, 2014, respectively	$ 37,940,641	$ 37,883,877	$ 36,240,838
Accumulated share-based compensation	5,289,880	5,073,144	5,079,985
Accumulated deficit	(33,797,941)	(32,492,286)	(33,620,190)
Total shareholders' equity	9,432,580	10,464,735	7,700,633
Total Liabilities and Shareholders' Equity	$ 11,213,018	$ 14,827,715	$ 14,473,962

Condensed Interim Consolidated3

Condensed Interim Consolidated Balance Sheets (Parenthetical) - $ / shares None in scaling factor is -9223372036854775296	Jun. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Condensed Interim Consolidated Balance Sheets [Abstract]
Common shares, par value
Common shares, shares issued	79,546,650	79,419,850	78,268,850
Common shares, shares outstanding	79,546,650	79,419,850	78,268,850

Condensed Interim Consolidated4

Condensed Interim Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Contract services revenue	$ 45,000	$ 60,000	$ 150,000	$ 147,000
Product sales	$ 112,748	$ 12,538	$ 408,036	70,994
Grant revenue				27,740
Revenues	$ 157,748	$ 72,538	$ 558,036	245,734
Expenses:
Costs of contract services	34,434	41,075	110,891	78,739
Costs of production and aquaculture	$ 251,004	$ 147,907	$ 661,644	442,820
Grant costs				27,740
Research and development	$ 129,710	$ 543,233	$ 830,115	1,824,554
General and administration	618,185	612,468	2,346,019	2,280,268
Total Expenses	1,033,333	1,344,683	3,948,669	4,654,121
Other Income (Loss)
Foreign exchange gain (loss)	77,468	146,302	(391,190)	(52,527)
Gain (loss) in fair value of warrant liability	1,254,029	4,528,450	2,455,361	833,862
Investment income	17,074	14,719	48,607	45,534
Other Income (Loss), Total	1,348,571	4,689,471	2,112,778	826,869
Income (Loss) Before Income Tax	472,986	3,417,326	(1,277,855)	(3,581,518)
Income tax expense	9,000	9,000	27,800	21,200
Net Income (Loss)	$ 463,986	$ 3,408,326	$ (1,305,655)	$ (3,602,718)
Income (loss) per common share - basic	$ 0.01	$ 0.04	$ (0.02)	$ (0.05)
Income (loss) per common share - diluted	$ 0.01	$ 0.04	$ (0.02)	$ (0.05)
Weighted average number of common shares outstanding: Basic	79,546,650	76,237,455	79,517,791	76,299,105
Weighted average number of common shares outstanding: Diluted	85,020,352	86,898,996	79,517,791	76,299,105

Condensed Interim Consolidated5

Condensed Interim Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash Flows Used In Operating Activities:
Net loss	$ (1,305,655)	$ (3,602,718)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	119,410	120,507
Share-based compensation	244,781	770,777
Foreign exchange (gain) loss	391,190	52,527
(Gain) loss in fair value of warrant liability	(2,455,361)	(833,862)
Changes in working capital items:
Accounts receivable	(69,242)	$ 163,331
Inventory	(159,476)
Prepaid expenses	(137,939)	$ (106,237)
Accounts payable and accrued liabilities	(211,667)	$ (224,629)
Deferred revenue	86,666
Net cash used in operating activities	(3,497,293)	$ (3,660,304)
Cash Flows From Investing Activities:
Acquisition of property, plant and equipment	(202,997)	$ (278,401)
Proceeds on maturities of short-term investments	419,283
Net cash provided by (used in) investing activities	216,286	$ (278,401)
Cash Flows From Financing Activities:
Proceeds from exercise of warrants and options	28,719	2,963,162
Net cash provided by financing activities	28,719	2,963,162
Effect of exchange rate changes on cash and cash equivalents	(356,207)	(60,321)
Net change in cash and cash equivalents	(3,608,495)	(1,035,864)
Cash and cash equivalents - beginning of period	13,769,953	15,478,038
Cash and cash equivalents - end of period	$ 10,161,458	$ 14,442,174

Nature of Operations

Nature of Operations	9 Months Ended
	Jun. 30, 2015
Nature of Operations [Abstract]
Nature of Operations	1. Nature of Operations Stellar Biotechnologies, Inc. (“the Company”) is organized under the laws of British Columbia, Canada. The Company's common shares are quoted on the U.S. OTCQB Marketplace Exchange under the trading symbol, SBOTF, and are listed on the TSX Venture Exchange as a Tier 2 issuer under the trading symbol, KLH. On April 7, 2010, the Company changed its name from CAG Capital, Inc. to Stellar Biotechnologies, Inc. On April 12, 2010, the Company completed a reverse merger transaction with Stellar Biotechnologies, Inc. a California corporation, which was founded in September 1999, and remains the Company's wholly-owned subsidiary and principal operating entity. The Company's executive offices are located at 332 E. Scott Street, Port Hueneme, California, 93041, USA, and its registered and records office is Royal Centre, 1055 West Georgia Street, Suite 1500, Vancouver, BC, V6E 4N7, Canada. Nature of Operations The Company's business is the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (“KLH”). The Company markets and distributes its KLH products to biotechnology and pharmaceutical companies, academic institutions, and clinical research organizations in Europe, the United States, and Asia. Management Plans For the nine months ended June 30, 2015 and 2014, the Company reported net losses of approximately $1.3 million and $3.6 million, respectively. The most significant factor in the fluctuations in net income and losses relates to noncash changes in the fair value of warrant liability, which was a gain of $2.5 million and $0.8 million for the nine months ended June 30, 2015 and 2014, respectively. As of June 30, 2015, the Company had an accumulated deficit of approximately $33.8 million and working capital of approximately $ 8.9 In the past, operations of the Company have primarily been funded by the issuance of common shares, exercise of warrants, grant revenues, contract services revenue, and product sales. In September 2013, the Company closed a private placement with gross proceeds of $ 12 The accompanying condensed interim consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business. Functional Currency The condensed interim consolidated financial statements of the Company are presented in U.S. dollars, unless otherwise stated, which is the Company's functional currency.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Jun. 30, 2015
Basis of Presentation [Abstract]
Basis of Presentation	2. Basis of Presentation The accompanying unaudited condensed interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q. They do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP for complete financial statements. These condensed interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes contained in the Company's Annual Report on Form 10-K for the year ended August 31, 2014. The accompanying condensed interim consolidated The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from these estimates. Change in Fiscal Year End On June 3, 2014, the Board of Directors of the Company approved a change in the Company's fiscal year end from August 31 to September 30 of each year. This change to the calendar quarter reporting cycle began September 1, 2014. As a result of the change, the Company had a one-month transition period from September 1, 2014 to September 30, 2014. The unaudited results for the one month ended September 30, 2014 are included in the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2014, as filed on February 9, 2015 with the SEC. The unaudited balance sheet at September 30, 2014 is included in these condensed interim consolidated financial statements for comparative purposes. The audited results for the one month ended September 30, 2014 will be included in the Company's Annual Report on Form 10-K for the fiscal year ending September 30, 2015, if not filed with the SEC prior thereto. In addition, the results for the three months and nine months ended June 30, 2015 are compared with the results of the three months and nine months ended June 30, 2014, which have been recast on a calendar quarter basis due to the change in the Company's fiscal year end from August 31 to September 30.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Jun. 30, 2015
Significant Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Recent Accounting Pronouncements Revenue from Contracts with Customers (Topic 606) Other Assets and Deferred Costs: Contracts with Customers In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern . ASU 2014-15 defines management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. The guidance in ASU 2014-15 is effective for annual reporting periods beginning after , with early application permitted. Management is in the process of assessing the impact of ASU 2014-15 on the Company's financial statements. Simplifying the Measurement of Inventory (Topic 330)

Inventory

Inventory	9 Months Ended
	Jun. 30, 2015
Inventory [Abstract]
Inventory	4. Inventory The Company records inventory for custom manufacturing of products for specific customers, including manufacturing under supply agreements. Raw materials include inventory of manufacturing supplies. Work in process includes manufacturing supplies, direct and indirect labor, contracted manufacturing and testing, and allocated manufacturing overhead for custom manufacturing in process at the end of the period. Finished goods include custom manufactured products that are complete, but not yet shipped to the customers. There was no inventory for custom manufactured products at August 31, 2014. Inventory consisted of the following at June 30, 2015 and September 30, 2014: June 30, September 30, 2015 2014 Raw materials $ 5,573 $ 10,480 Work in process 80,720 24,411 Finished goods 108,074 - $ 194,367 $ 34,891

Property, Plant and Equipment,

Property, Plant and Equipment, net	9 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment, net [Abstract]
Property, Plant and Equipment, net	5 Property, Plant and Equipment, net Property, plant and equipment, net consisted of the following: June 30, September 30, August 31, 2015 2014 2014 Aquaculture system $ 58,923 $ 58,923 $ 58,923 Laboratory facilities 62,033 62,033 62,033 Computer and office equipment 77,678 77,697 77,697 Tools and equipment 700,011 635,766 622,289 Vehicles 10,997 10,997 10,997 Leasehold improvements 109,800 61,187 61,187 1,019,442 906,603 893,126 Less: accumulated depreciation (636,962 ) (518,263 ) (505,734 ) Depreciable assets, net 382,480 388,340 387,392 Construction in progress 89,447 - - $ 471,927 $ 388,340 $ 387,392 Depreciation expense amounted to $ 41,808 34,307 119,410 99,078

Intangible Assets - Licensing R

Intangible Assets - Licensing Rights	9 Months Ended
	Jun. 30, 2015
Intangible Assets - Licensing Rights [Abstract]
Intangible Assets - Licensing Rights	6. Intangible Assets - Licensing Rights In December 2010, the Company entered into a research collaboration agreement with a customer. When the agreement terminated according to its terms in August 2011, the Company acquired an exclusive, worldwide sub-licensable and royalty-free license for certain technology developed in collaboration with the customer. The Company paid a $ 200,000 seven Amortization expense amounted to $ 7,143 21,429

Commitments

Commitments	9 Months Ended
	Jun. 30, 2015
Commitments [Abstract]
Commitments	7. Commitments Operating leases The Company leases three buildings and facilities used in its operations under sublease agreements with the Port Hueneme Surplus Property Authority. In June 2015, the Company exercised its option to extend these sublease agreements for an additional five five The Company leases facilities used for executive offices and laboratories. The Company must pay a portion of the common area maintenance. In July 2014, the Company exercised its option to extend this lease for a two In June 2015, the Company began leasing undeveloped land in Baja California, Mexico to assess its suitability for the long-term development and potential expansion of the Company's production capability. The first two years of rent under the lease were prepaid in June 2015. The initial term is three 30 Future minimum lease payments are as follows: June 30, 2015 For The Year Ending September 30, 2015 $ 57,000 2016 157,000 2017 143,000 2018 106,000 2019 106,000 2020 106,000 Thereafter 6,000 $ 681,000 Rent expense on these lease agreements amounted to approximately $ 137,000 135,000 Purchase obligations The Company has commitments totaling approximately $ 152,000 25,000 Supply agreements The Company has three commitments under certain supply agreements with customers for fixed prices per gram on a non-exclusive basis except within that customer's field of use. One amended and restated supply agreement replaced two prior agreements that automatically renewed each year. The new agreement is effective March 2015 through March 2020 and is renewable for one-year terms upon written request of the customer. One agreement is effective October 2014 through October 2019 and is renewable for one-year terms upon written request of the customer. One agreement is effective October 2014 through October 2017 and is renewable for one-year terms upon written request of the customer. Licensing fees In July 2013, the Company acquired the exclusive, worldwide license to certain patented technology for the development of human immunotherapies against Clostridium difficile 25,000 200,000 20,000 No 50,000 26,000 The license agreement expires when the last valid patent claim licensed under the license agreement expires. Prior to that time, the license agreement can be terminated by the licensor upon certain conditions. The Company will have 30 three Upon execution of the license agreement, the Company issued 371,200 278,400 The license agreement provides for the Company to pay up to an aggregate of $ 6,020,000 57,025,000 100,000 no Retirement savings plan 401 The Company sponsors a 401 3 21 100 45,000 40,000 2014 Related party commitments See Note 9 “Related Party Disclosures”.

Share Capital

Share Capital	9 Months Ended
	Jun. 30, 2015
Share Capital [Abstract]
Share Capital	8. Share Capital The Company had the following transactions in share capital: Nine Months Ended June 30, June 30, 2015 2014 Number of common shares issued 126,800 6,475,820 Proceeds from exercise of warrants and broker units $ 938 $ 2,587,014 Transfer to common shares on exercise of warrants and broker units 426 5,308,382 Proceeds from exercise of options 27,781 376,148 Transfer to common shares on exercise of options 27,619 341,594 Share-based compensation 244,781 770,777 Performance shares There were 10,000,000 At June 30, 2015, there are 3,838,383 Black-Scholes option valuation model The Company uses the Black-Scholes option valuation model to determine the fair value of warrants, broker units and stock options. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company has used historical volatility to estimate the volatility of the share price. Changes in the subjective input assumptions can materially affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company's warrants, broker units and stock options. Warrants A summary of the Company's warrants activity is as follows: Number of Warrants Weighted Average Exercise Price Balance - September 30, 2014 10,545,312 $ 1.01 CDN $ Exercised (600 ) 0.75 CDN $ Expired (278,700 ) 1.25 CDN $ Balance - June 30, 2015 10,266,012 $ 1.13 CDN $ The weighted average contractual life remaining on the outstanding warrants at June 30, 2015 is .84 The following table summarizes information about the outstanding warrants at June 30, 2015: Exercise Price Number of Expiry Date CDN$ 0.40 4,000,000 October 25, 2015 CDN$ 0.40 278,400 January 4, 2016 $ 1.35 4,701,902 September 9, 2016 $ 1.05 200,000 September 9, 2016 Broker warrants $ 1.35 952,377 September 20, 2016 $ 1.05 133,333 September 20, 2016 Broker warrants 10,266,012 Warrant liability Equity offerings conducted by the Company in prior years included the issuance of warrants with exercise prices denominated in Canadian dollars. The Company's functional currency is the U.S. dollar. As a result of having exercise prices denominated in other than the Company's functional currency, these warrants meet the definition of derivatives and are therefore classified as derivative liabilities measured at fair value with adjustments to fair value recognized through the consolidated statements of operations. As these warrants are exercised, the fair value of the recorded warrant liability on date of exercise is included in common shares along with the proceeds from the exercise. If these warrants expire, the related decrease in warrant liability is recognized in profit or loss, as part of the change in fair value of warrant liability. There is no cash flow impact as a result of this accounting treatment. The fair value of the warrants is determined using the Black-Scholes option valuation model at the end of each reporting period. Upon exercise of the warrants, the fair value of warrants included in derivative liabilities is reclassified to equity. The fair value of warrants exercised during the nine months ended June 30, 2015 and 2014 was determined using the Black-Scholes option valuation model, using the following weighted average assumptions: Nine Months Ended June 30, 2015 June 30, 2014 Risk free interest rate 1.12 % 1.07 % Expected life (years) 0.01 0.29 Expected share price volatility 97 % 106 % There were no Broker units The Company granted broker units as finders' fees in conjunction with equity offerings in prior years. Broker units are fully vested when granted and allow the holders to purchase equity units. A unit consists of one one one A summary of broker units activity is as follows: Number of Units Weighted Average Exercise Price Balance - September 30, 2014 467,200 $ 0.25 CDN $ Exercised (1,200 ) 0.50 CDN $ Balance - June 30, 2015 466,000 $ 0.25 CDN $ The weighted average contractual life remaining on the outstanding broker units is 0.35 The following table summarizes information about the outstanding broker units at June 30, 2015: Exercise Price Number of Expiry Date CDN$ 0.25 400,000 October 25, 2015 CDN$ 0.25 66,000 January 4, 2016 466,000 The outstanding broker units at June 30, 2015 include one There were no Options The Company has a 2013 fixed stock option plan (“the Plan”) administered by the Board of Directors, who have the discretion to grant up to an aggregate of 10,000,000 (a) One (b) One 12 (c) One 18 Stock options granted to investor relations consultants vest over a period of not less than 12 25 three 25 three Options have been granted under the Plan allowing the holders to purchase common shares of the Company as follows: Number of Options Weighted Average Exercise Price Balance - September 30, 2014 5,885,533 $ 0.62 CDN $ Granted 165,000 1.33 CDN $ Exercised (125,000 ) 0.25 CDN $ Balance - June 30, 2015 5,925,533 $ 0.67 CDN $ The weighted average contractual life remaining on the outstanding options is 3.48 The following table summarizes information about the options under the Plan outstanding and exercisable at June 30, 2015: Exercise Price Number of Exercisable at Expiry Date CDN$ 0.28 1,645,000 1,645,000 April 9, 2017 CDN$ 0.25 55,000 55,000 May 17, 2017 CDN$ 0.28 20,000 20,000 June 28, 2017 CDN$ 0.28 70,000 70,000 July 13, 2017 CDN$ 0.64 70,000 70,000 October 25, 2017 CDN$ 1.00 60,000 60,000 February 10, 2018 CDN$ 0.65 848,600 848,600 August 8, 2018 CDN$ 0.50 5,000 5,000 September 26, 2018 CDN$ 1.87 100,000 100,000 November 7, 2018 CDN$ 0.40 70,000 70,000 December 22, 2018 CDN$ 0.42 853,600 853,600 April 13, 2019 CDN$ 0.29 90,000 90,000 June 18, 2019 CDN$ 0.37 150,000 150,000 August 9, 2019 CDN$ 0.37 150,000 150,000 August 16, 2019 CDN$ 0.25 8,333 8,333 October 23, 2019 CDN$ 0.25 215,000 215,000 December 19, 2019 CDN$ 0.58 560,000 560,000 May 14, 2020 CDN$ 0.58 100,000 100,000 May 23, 2020 $ 1.83 495,000 495,000 November 1, 2020 $ 1.84 100,000 100,000 November 15, 2020 CDN$ 0.94 95,000 63,333 June 27, 2021 CDN$ 1.52 115,000 38,333 November 12, 2021 CDN$ 0.89 50,000 16,667 June 10, 2022 5,925,533 5,783,866 The estimated fair value of the stock options granted during the nine months ended June 30, 2015 and 2014 was determined using a Black-Scholes option valuation model with the following weighted average assumptions. Nine Months Ended June 30, 2015 June 30, 2014 Risk free interest rate 1.65 % 2.01 % Expected life (years) 7.00 6.75 Expected share price volatility 115 % 120 % Expected dividend yield 0 % 0 % The weighted average fair value of stock options awarded during the nine months ended June 30, 2015 and 2014 was CDN$ 1.17 1.51 As of June 30, 2015, the Company had approximately $ 66,000 1.51 The intrinsic value of the options exercised during the nine months ended June 30, 2015 and 2014 was CDN$ 1.15 1.32 0.27

Related Party Disclosures

Related Party Disclosures	12 Months Ended
	Aug. 31, 2014
Related Party Disclosures [Abstract]
Related Party Disclosures	9. Related Party Disclosures 5 500,000 Collaboration agreement In December 2013, the Company entered into a collaboration agreement with a privately-held Taiwan biopharmaceuticals manufacturer and a beneficial owner of over 5 822 no

Supplemental Disclosure of Cash

Supplemental Disclosure of Cash Flow and Non-Cash Transactions	9 Months Ended
	Jun. 30, 2015
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Supplemental Disclosure of Cash Flow and Non-Cash Transactions	10. Supplemental Disclosure of Cash Flow and Non-Cash Transactions Supplemental disclosure of cash flow information follows: Nine Months Ended June 30, June 30, 2015 2014 Cash paid during the period for taxes $ 27,800 $ 21,200 Supplemental disclosure of noncash financing and investing activities follows: Nine Months Ended June 30, June 30, 2015 2014 Transfer to common shares on exercise of warrants and broker units $ 426 $ 5,308,382 Transfer to common shares on exercise of options 27,619 341,594

Concentrations of Credit Risk

Concentrations of Credit Risk	12 Months Ended
	Aug. 31, 2014
Concentrations of Credit Risk [Abstract]
Concentrations of Credit Risk	11. Concentrations of Credit Risk Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash, cash equivalents and accounts receivable. Management's assessment of the Company's credit risk for cash and cash equivalents is low as cash and cash equivalents are held in financial institutions believed to be credit worthy. The Company limits its exposure to credit loss by placing its cash with major financial institutions and invests only in short-term obligations. Approximately 67 63 the National Science Foundation. Approximately 99 76 81 While the Company is exposed to credit losses due to the non-performance of its counterparties, the Company considers the risk of this remote. The Company estimates its maximum credit risk for accounts receivable at the amount recorded on the balance sheet.

Subsequent Event

Subsequent Event	9 Months Ended
	Jun. 30, 2015
Subsequent Event [Abstract]
Subsequent Event	12. Subsequent Event In July 2015, the Company entered into an exclusive collaboration agreement with Ostiones Guerrero SA de CV (“Ostiones”) in Baja California, Mexico for the potential development of an additional aquaculture locale and expansion of production, subject to a site suitability study to be conducted over the next three years. Under the terms of the agreement, the Company and Ostiones will collaborate on the design, expansion and development of marine aquaculture resources and KLH production facilities in Baja California, Mexico to provide, exclusively for the Company, an additional site for hatchery and maturation of keyhole limpets and production of KLH. Ostiones will provide local manpower, labor and operational support to the Company, the costs of which are subject to prior approval and will be reimbursed by the Company on a monthly basis. As part of the collaboration, Ostiones will gain access to the Company's advanced aquaculture techniques, proprietary expertise, support services and training to facilitate the expansion of Ostiones' seafood production business. During the three year term of the agreement and for five years thereafter, the parties are subject to customary non-competition and non-contravention provisions. The Company will be responsible for certain improvements to the leased undeveloped land in Baja California, Mexico described in Note 7, including construction of certain structures and a power-generating facility which will be owned by the Company. The collaboration agreement is co-terminus with the date of the initial expiration of that lease in June 2018, unless terminated earlier.

Significant Accounting Polici18

Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2015
Significant Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Revenue from Contracts with Customers (Topic 606) Other Assets and Deferred Costs: Contracts with Customers In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern . ASU 2014-15 defines management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. The guidance in ASU 2014-15 is effective for annual reporting periods beginning after , with early application permitted. Management is in the process of assessing the impact of ASU 2014-15 on the Company's financial statements. Simplifying the Measurement of Inventory (Topic 330)

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Jun. 30, 2015
Inventory [Abstract]
Inventory	June 30, September 30, 2015 2014 Raw materials $ 5,573 $ 10,480 Work in process 80,720 24,411 Finished goods 108,074 - $ 194,367 $ 34,891

Property, Plant and Equipment20

Property, Plant and Equipment, net (Tables)	9 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment, net [Abstract]
Property, Plant and Equipment, net	June 30, September 30, August 31, 2015 2014 2014 Aquaculture system $ 58,923 $ 58,923 $ 58,923 Laboratory facilities 62,033 62,033 62,033 Computer and office equipment 77,678 77,697 77,697 Tools and equipment 700,011 635,766 622,289 Vehicles 10,997 10,997 10,997 Leasehold improvements 109,800 61,187 61,187 1,019,442 906,603 893,126 Less: accumulated depreciation (636,962 ) (518,263 ) (505,734 ) Depreciable assets, net 382,480 388,340 387,392 Construction in progress 89,447 - - $ 471,927 $ 388,340 $ 387,392

Commitments (Tables)

Commitments (Tables)	9 Months Ended
	Jun. 30, 2015
Commitments [Abstract]
Schedule of Future Minimum Lease Payments	Future minimum lease payments are as follows: June 30, 2015 For The Year Ending September 30, 2015 $ 57,000 2016 157,000 2017 143,000 2018 106,000 2019 106,000 2020 106,000 Thereafter 6,000 $ 681,000

Share Capital (Tables)

Share Capital (Tables)	9 Months Ended
	Jun. 30, 2015
Share Capital [Abstract]
Transactions In Share Capital	Nine Months Ended June 30, June 30, 2015 2014 Number of common shares issued 126,800 6,475,820 Proceeds from exercise of warrants and broker units $ 938 $ 2,587,014 Transfer to common shares on exercise of warrants and broker units 426 5,308,382 Proceeds from exercise of options 27,781 376,148 Transfer to common shares on exercise of options 27,619 341,594 Share-based compensation 244,781 770,777
Schedule of Warrant Activity	Number of Warrants Weighted Average Exercise Price Balance - September 30, 2014 10,545,312 $ 1.01 CDN $ Exercised (600 ) 0.75 CDN $ Expired (278,700 ) 1.25 CDN $ Balance - June 30, 2015 10,266,012 $ 1.13 CDN $
Summary of Warrants Outstanding	Exercise Price Number of Expiry Date CDN$ 0.40 4,000,000 October 25, 2015 CDN$ 0.40 278,400 January 4, 2016 $ 1.35 4,701,902 September 9, 2016 $ 1.05 200,000 September 9, 2016 Broker warrants $ 1.35 952,377 September 20, 2016 $ 1.05 133,333 September 20, 2016 Broker warrants 10,266,012
Schedule of Fair Value Of Warrants Exercised, Valuation Assumptions	Nine Months Ended June 30, 2015 June 30, 2014 Risk free interest rate 1.12 % 1.07 % Expected life (years) 0.01 0.29 Expected share price volatility 97 % 106 %
Schedule of Broker Units Activity	Number of Units Weighted Average Exercise Price Balance - September 30, 2014 467,200 $ 0.25 CDN $ Exercised (1,200 ) 0.50 CDN $ Balance - June 30, 2015 466,000 $ 0.25 CDN $
Summary Of Broker Units Outstanding	Exercise Price Number of Expiry Date CDN$ 0.25 400,000 October 25, 2015 CDN$ 0.25 66,000 January 4, 2016 466,000
Schedule of Share-based Compensation Stock Options Activity	Number of Options Weighted Average Exercise Price Balance - September 30, 2014 5,885,533 $ 0.62 CDN $ Granted 165,000 1.33 CDN $ Exercised (125,000 ) 0.25 CDN $ Balance - June 30, 2015 5,925,533 $ 0.67 CDN $
Summary of Options Outstanding And Exercisable	The following table summarizes information about the options under the Plan outstanding and exercisable at June 30, 2015: Exercise Price Number of Exercisable at Expiry Date CDN$ 0.28 1,645,000 1,645,000 April 9, 2017 CDN$ 0.25 55,000 55,000 May 17, 2017 CDN$ 0.28 20,000 20,000 June 28, 2017 CDN$ 0.28 70,000 70,000 July 13, 2017 CDN$ 0.64 70,000 70,000 October 25, 2017 CDN$ 1.00 60,000 60,000 February 10, 2018 CDN$ 0.65 848,600 848,600 August 8, 2018 CDN$ 0.50 5,000 5,000 September 26, 2018 CDN$ 1.87 100,000 100,000 November 7, 2018 CDN$ 0.40 70,000 70,000 December 22, 2018 CDN$ 0.42 853,600 853,600 April 13, 2019 CDN$ 0.29 90,000 90,000 June 18, 2019 CDN$ 0.37 150,000 150,000 August 9, 2019 CDN$ 0.37 150,000 150,000 August 16, 2019 CDN$ 0.25 8,333 8,333 October 23, 2019 CDN$ 0.25 215,000 215,000 December 19, 2019 CDN$ 0.58 560,000 560,000 May 14, 2020 CDN$ 0.58 100,000 100,000 May 23, 2020 $ 1.83 495,000 495,000 November 1, 2020 $ 1.84 100,000 100,000 November 15, 2020 CDN$ 0.94 95,000 63,333 June 27, 2021 CDN$ 1.52 115,000 38,333 November 12, 2021 CDN$ 0.89 50,000 16,667 June 10, 2022 5,925,533 5,783,866
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Nine Months Ended June 30, 2015 June 30, 2014 Risk free interest rate 1.65 % 2.01 % Expected life (years) 7.00 6.75 Expected share price volatility 115 % 120 % Expected dividend yield 0 % 0 %

Supplemental Disclosure of Ca23

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Tables)	9 Months Ended
	Jun. 30, 2015
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Supplemental Disclosure of Cash Flow Information	Nine Months Ended June 30, June 30, 2015 2014 Cash paid during the period for taxes $ 27,800 $ 21,200
Supplemental Disclosure of Non-Cash Financing and Investing Activities	Nine Months Ended June 30, June 30, 2015 2014 Transfer to common shares on exercise of warrants and broker units $ 426 $ 5,308,382 Transfer to common shares on exercise of options 27,619 341,594

Nature of Operations (Details)

Nature of Operations (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2014	Aug. 31, 2014
Nature of Operations [Abstract]
Net income (loss)		$ 463,986	$ 3,408,326	$ (1,305,655)	$ (3,602,718)
Accumulated deficit		(33,797,941)		(33,797,941)		$ (32,492,286)	$ (33,620,190)
Working capital		8,900,000		8,900,000
Changes in fair value of warrant liability		$ 1,254,029	$ 4,528,450	$ 2,455,361	$ 833,862
Proceeds from a private placement	$ 12,000,000

Inventory (Details)

Inventory (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Inventory [Abstract]
Raw materials	$ 5,573	$ 10,480
Work in process	80,720	$ 24,411
Finished goods	108,074
Inventory	$ 194,367	$ 34,891

Property, Plant and Equipment26

Property, Plant and Equipment, net (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment, net [Abstract]
Depreciation expense	$ 41,808	$ 34,307	$ 119,410	$ 99,078

Property, Plant and Equipment27

Property, Plant and Equipment, net (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	$ 1,019,442	$ 906,603	$ 893,126
Less: accumulated depreciation	(636,962)	(518,263)	(505,734)
Depreciable assets, net	382,480	$ 388,340	$ 387,392
Construction in progress	89,447
Property, plant and equipment, net	471,927	$ 388,340	$ 387,392
Aquaculture system [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	58,923	58,923	58,923
Laboratory facilities [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	62,033	62,033	62,033
Computer and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	77,678	77,697	77,697
Tools and equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	700,011	635,766	622,289
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	10,997	10,997	10,997
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	$ 109,800	$ 61,187	$ 61,187

Intangible Assets - Licensing28

Intangible Assets - Licensing Rights (Details) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Aug. 31, 2011
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 7,143		$ 21,429
Licensing Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Licence fee for the licensing rights				$ 200,000
Estimated useful life		7 years

Commitments (Narrative) (Detail

Commitments (Narrative) (Details) - USD ($)	9 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Aug. 31, 2014	Aug. 31, 2013
Operating Leased Assets [Line Items]
Rent expense on lease agreements	$ 137,000	$ 135,000
Three buildings and facilities used in its operations [Member]
Operating Leased Assets [Line Items]
Lease agreement, contract term	5 years
Lease agreement, renewal term	5 years
Lease contract/renewal start date	2015-10
Facilities used for executive offices and laboratories [Member]
Operating Leased Assets [Line Items]
Lease agreement, renewal term	2 years
Lease contract/renewal start date	2014-07
Undeveloped land in Baja, Mexico
Operating Leased Assets [Line Items]
Lease agreement, contract term	3 years
Lease agreement, renewal term	30 years
Lease contract/renewal start date	2015-06
Agreements with contract manufacturing organizations and consultants [Member]
Purchase Obligations [Line items]
Purchase obligations	$ 152,000
Agreements to pay time and materials to contractors [Member]
Purchase Obligations [Line items]
Purchase obligations	25,000
401(k) Retirement Savings Plan [Member]
Other Commitments [Line Items]
Employer contributions	$ 45,000	40,000
Employee vesting percentage	100.00%
Annual non-elective safe harbor employer contribution	3.00%
Licensing Agreements [Member]
Other Commitments [Line Items]
License costs			$ 200,000	$ 25,000
Annual license fee	$ 20,000
Annual license fee, start date	2014-09
Patent cost reimbursement	$ 50,000	$ 26,000
Common shares issued upon execution of license agreement				371,200
Common shares to be called by warrants				278,400
Aggregate milestone payments upon achievement of financing and development targets	6,020,000
Contingent milestone payments due upon achievement of sales target	$ 57,025,000
Milestone payment			$ 100,000

Commitments (Schedule of Future

Commitments (Schedule of Future Minimum Lease Payments) (Details)	Jun. 30, 2015USD ($)
For The Year Ending September 30,
2,015	$ 57,000
2,016	157,000
2,017	143,000
2,018	106,000
2,019	106,000
2,020	106,000
Thereafter	6,000
Future minimum lease payments, total	$ 681,000

Share Capital (Schedule of Tran

Share Capital (Schedule of Transactions In Share Capital) (Details) - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share Capital [Abstract]
Number of common shares issued	126,800	6,475,820
Proceeds from exercise of warrants and broker units	$ 938	$ 2,587,014
Transfer to common shares on exercise of warrants and broker units	426	5,308,382
Proceeds from exercise of options	27,781	376,148
Transfer to common shares on exercise of options	27,619	341,594
Share-based compensation	$ 244,781	$ 770,777

Share Capital (Schedule of Warr

Share Capital (Schedule of Warrants Activity) (Details) - 9 months ended Jun. 30, 2015 - CAD / shares	Total
Share Capital [Abstract]
Number of Warrants, Beginning Balance	10,545,312
Number of Warrants Exercised	(600)
Number of Warrants Expired	(278,700)
Number of Warrants, Ending Balance	10,266,012
Weighted Average Exercise Price, Beginning Balance	CAD 1.01
Weighted Average Exercise Price, Exercised	0.75
Weighted Average Exercise Price, Expired	1.25
Weighted Average Exercise Price, Ending Balance	CAD 1.13

Share Capital (Summary of Outst

Share Capital (Summary of Outstanding Warrants) (Details)	9 Months Ended
	Jun. 30, 2015$ / sharesshares	Jun. 30, 2015CAD / sharesshares	Sep. 30, 2014CAD / sharesshares
Class of Warrant or Right [Line Items]
Exercise Price | CAD / shares		CAD 1.13	CAD 1.01
Number of Warrants	10,266,012	10,266,012	10,545,312
Warrant One [Member]
Class of Warrant or Right [Line Items]
Exercise Price | CAD / shares		CAD 0.40
Number of Warrants	4,000,000	4,000,000
Expiry Date	Oct. 25, 2015
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price | CAD / shares		CAD 0.40
Number of Warrants	278,400	278,400
Expiry Date	Jan. 4, 2016
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Exercise Price | $ / shares	$ 1.35
Number of Warrants	4,701,902	4,701,902
Expiry Date	Sep. 9, 2016
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Exercise Price | $ / shares	$ 1.35
Number of Warrants	952,377	952,377
Expiry Date	Sep. 20, 2016
Broker warrants [Member] | Warrant Four [Member]
Class of Warrant or Right [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Warrants	200,000	200,000
Expiry Date	Sep. 9, 2016
Broker warrants [Member] | Warrant Six [Member]
Class of Warrant or Right [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Warrants	133,333	133,333
Expiry Date	Sep. 20, 2016

Share Capital (Schedule Of Wa34

Share Capital (Schedule Of Warrants Exercised, Fair Value Assumptions) (Details) - Warrants Exercised [Member]	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Class of Warrant or Right [Line Items]
Risk free interest rate	1.12%	1.07%
Expected life (years)	4 days	3 months 14 days
Expected share price volitility	97.00%	106.00%

Share Capital (Schedule of Brok

Share Capital (Schedule of Broker Units Activity) (Details) - 9 months ended Jun. 30, 2015 - CAD / shares	Total
Share Capital [Abstract]
Number of units, Beginning Balance	467,200
Number of units, Exercised	(1,200)
Number of units, Ending Balance	466,000
Weighted average exercise price, Beginning Balance	CAD 0.25
Weighted average exercise price, Exercised	0.50
Weighted average exercise price, Ending Balance	CAD 0.25

Share Capital (Summary of Out36

Share Capital (Summary of Outstanding Broker Units) (Details) - CAD / shares	9 Months Ended
	Jun. 30, 2015	Sep. 30, 2014
Class of Warrant or Right [Line Items]
Number of Units	466,000	467,200
Broker Unit One [Member]
Class of Warrant or Right [Line Items]
Exercise Price	CAD 0.25
Number of Units	400,000
Expiry Date	Oct. 25, 2015
Broker Unit Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price	CAD 0.25
Number of Units	66,000
Expiry Date	Jan. 4, 2016

Share Capital (Schedule of Stoc

Share Capital (Schedule of Stock Option Activity) (Details) - 9 months ended Jun. 30, 2015 - CAD / shares	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	5,885,533
Number of Options, Granted	165,000
Number of Options, Exercised	(125,000)
Number of Options, Ending Balance	5,925,533
Weighted Average Exercise Price, Beginning Balance	CAD 0.62
Weighted Average Exercise Price, Granted	1.33
Weighted Average Exercise Price, Exercised	0.25
Weighted Average Exercise Price, Ending Balance	CAD 0.67

Share Capital (Summary of Stock

Share Capital (Summary of Stock Options Outstanding and Exercisable) (Details)	9 Months Ended
	Jun. 30, 2015$ / sharesshares	Jun. 30, 2015CAD / sharesshares	Sep. 30, 2014shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	5,925,533	5,925,533	5,885,533
Exercisable at June 30, 2015	5,783,866	5,783,866
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.28
Number of Options	1,645,000	1,645,000
Exercisable at June 30, 2015	1,645,000	1,645,000
Expiry Date	Apr. 9, 2017
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.25
Number of Options	55,000	55,000
Exercisable at June 30, 2015	55,000	55,000
Expiry Date	May 17, 2017
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.28
Number of Options	20,000	20,000
Exercisable at June 30, 2015	20,000	20,000
Expiry Date	Jun. 28, 2017
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.28
Number of Options	70,000	70,000
Exercisable at June 30, 2015	70,000	70,000
Expiry Date	Jul. 13, 2017
Stock Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.64
Number of Options	70,000	70,000
Exercisable at June 30, 2015	70,000	70,000
Expiry Date	Oct. 25, 2017
Stock Option Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 1
Number of Options	60,000	60,000
Exercisable at June 30, 2015	60,000	60,000
Expiry Date	Feb. 10, 2018
Stock Option Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.65
Number of Options	848,600	848,600
Exercisable at June 30, 2015	848,600	848,600
Expiry Date	Aug. 8, 2018
Stock Option Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.50
Number of Options	5,000	5,000
Exercisable at June 30, 2015	5,000	5,000
Expiry Date	Sep. 26, 2018
Stock Option Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 1.87
Number of Options	100,000	100,000
Exercisable at June 30, 2015	100,000	100,000
Expiry Date	Nov. 7, 2018
Stock Option Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.40
Number of Options	70,000	70,000
Exercisable at June 30, 2015	70,000	70,000
Expiry Date	Dec. 22, 2018
Stock Option Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.42
Number of Options	853,600	853,600
Exercisable at June 30, 2015	853,600	853,600
Expiry Date	Apr. 13, 2019
Stock Option Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.29
Number of Options	90,000	90,000
Exercisable at June 30, 2015	90,000	90,000
Expiry Date	Jun. 18, 2019
Stock Option Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.37
Number of Options	150,000	150,000
Exercisable at June 30, 2015	150,000	150,000
Expiry Date	Aug. 9, 2019
Stock Option Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.37
Number of Options	150,000	150,000
Exercisable at June 30, 2015	150,000	150,000
Expiry Date	Aug. 16, 2019
Stock Option Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.25
Number of Options	8,333	8,333
Exercisable at June 30, 2015	8,333	8,333
Expiry Date	Oct. 23, 2019
Stock Option Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.25
Number of Options	215,000	215,000
Exercisable at June 30, 2015	215,000	215,000
Expiry Date	Dec. 19, 2019
Stock Option Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.58
Number of Options	560,000	560,000
Exercisable at June 30, 2015	560,000	560,000
Expiry Date	May 14, 2020
Stock Option Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.58
Number of Options	100,000	100,000
Exercisable at June 30, 2015	100,000	100,000
Expiry Date	May 23, 2020
Stock Option Ninteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.83
Number of Options	495,000	495,000
Exercisable at June 30, 2015	495,000	495,000
Expiry Date	Nov. 1, 2020
Stock Option Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.84
Number of Options	100,000	100,000
Exercisable at June 30, 2015	100,000	100,000
Expiry Date	Nov. 15, 2020
Stock Option Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.94
Number of Options	95,000	95,000
Exercisable at June 30, 2015	63,333	63,333
Expiry Date	Jun. 27, 2021
Stock Option Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 1.52
Number of Options	115,000	115,000
Exercisable at June 30, 2015	38,333	38,333
Expiry Date	Nov. 12, 2021
Stock Option Twenty Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | CAD / shares		CAD 0.89
Number of Options	50,000	50,000
Exercisable at June 30, 2015	16,667	16,667
Expiry Date	Jun. 10, 2022

Share Capital (Schedule of St39

Share Capital (Schedule of Stock Options Granted, Fair Value Assumptions) (Details) - Employee Stock Option [Member]	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.65%	2.01%
Expected life (years)	7 years	6 years 9 months
Expected share price volitility	115.00%	120.00%
Expected dividend yield	0.00%	0.00%

Share Capital (Narrative) (Deta

Share Capital (Narrative) (Details)	9 Months Ended
	Jun. 30, 2015CADCAD / shares	Jun. 30, 2014CADCAD / shares	Jun. 30, 2015USD ($)shares	Aug. 31, 2012shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average contractual life remaining on the outstanding options	3 years 5 months 23 days
Weighted average fair value of stock options awarded | CAD / shares	CAD 1.17	CAD 1.51
Unrecognized share-based compensation expense | $			$ 66,000
Unrecognized share-based compensation expense, recognition period	1 year 6 months 4 days
Intrinsic value of the options exercised | CAD	CAD 1.15	CAD 1.32
Intrinsic value of the vested options | $			$ 0.27
Broker units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average contractual life remaining on the outstanding warrants or broker units	4 months 6 days
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average contractual life remaining on the outstanding warrants or broker units	10 months 3 days
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, shares reserved for issuance				10,000,000
Share based compensation, shares outstanding			3,838,383
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, shares reserved for issuance			10,000,000
Share based compensation, stock option vesting schedule	The exercise price of an option is set at the closing price of the Company's common shares on the date of grant. Stock options granted to directors, officers, employees and consultants are subject to the following vesting schedule: (a) One-third of the shares subject to the option shall vest immediately; (b) One-third of the shares subject to the option shall vest 12 months from the date of grant; and (c) One-third of the shares subject to the option shall vest 18 months from the date of grant. Stock options granted to investor relations consultants vest over a period of not less than 12 months with 25% of the shares subject to the option vesting on the date that is three months from the date of grant, and a further 25% vesting on each successive date that is three months from the date of the prior vesting.

Related Party Disclosures (Deta

Related Party Disclosures (Details) - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2013	Aug. 14, 2002
Director and Officer [Member] | Royalty Agreements [Member]
Related Party Transaction [Line Items]
Royalty percentage of gross receipts over base amount				5.00%
Gross receipt base amount for royalty calculation				$ 500,000
Royalty expense
A Taiwan Biopharmaceuticals Manufacturer and a Beneficial Owner [Member] | Collaborative Agreement [Member]
Related Party Transaction [Line Items]
Ownership percentage			5.00%

Supplemental Disclosure of Ca42

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Schedule of Supplemental Disclosure of Cash Flow Information) (Details) - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Cash paid during the period for taxes	$ 27,800	$ 21,200

Supplemental Disclosure of Ca43

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Schedule of Supplemental Disclosure of Non-cash Financing and Investing Activities) (Details) - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Transfer to common shares on exercise of warrants and broker units	$ 426	$ 5,308,382
Transfer to common shares on exercise of options	$ 27,619	$ 341,594

Concentrations of Credit Risk (

Concentrations of Credit Risk (Details) - Customer Concentration Risk [Member]	1 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Aug. 31, 2014
Accounts Receivable [Member] | One Customer [Member]
Concentration Risk [Line Items]
Concentration risk percentage		99.00%		76.00%
Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage	81.00%
Product Sales and Contract Services Revenue [Member] | Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage			63.00%
Product Sales and Contract Services Revenue [Member] | Three Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage		67.00%